Prostatic Neoplasms Castration-resistant
📧 Sign up to get email alerts when something new happens for Prostatic Neoplasms Castration-resistant.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-18EMA Authorised: Akeega (abiraterone acetate;niraparib (tosilate monohydrate))
Akeega, containing abiraterone acetate and niraparib tosilate monohydrate, has been authorised for castration-resistant prostatic neoplasms.
-
EMA approval · 2026-08-12EMA Authorised: Lynparza (olaparib) — AstraZeneca AB
Olaparib (Lynparza) has been authorised by the EMA for multiple indications across ovarian, breast, pancreatic, and castration-resistant pro…
-
EMA approval · 2026-07-20EMA Authorised: Pluvicto (lutetium (177Lu) vipivotide tetraxetan) — Novartis Europharm Limited
EU authorization of Pluvicto (lutetium-177Lu vipivotide tetraxetan) for prostatic neoplasms, castration-resistant.
-
EMA approval · 2026-06-03EMA Authorised: Lynparza (olaparib) — AstraZeneca AB
Olaparib (Lynparza) has been authorised by the EMA for multiple neoplasms including ovarian, breast, pancreatic, and castration-resistant pr…